Olga Reshetko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8668791/publications.pdf

Version: 2024-02-01

932766 1058022 5,942 18 10 14 citations g-index h-index papers 19 19 19 7707 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region. Farmakoekonomika, 2022, 14, 462-467.	0.4	O
2	The rationality of recommendations of drugs for patients with cephalgia in simulated situations in the pharmacy. Kachestvennaya Klinicheskaya Praktika, 2022, , 27-43.	0.2	1
3	A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children. Human Vaccines and Immunotherapeutics, 2021, , 1-12.	1.4	1
4	Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment. Kachestvennaya Klinicheskaya Praktika, 2021, , 50-56.	0.2	1
5	Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clinical and Experimental Rheumatology, 2020, 38, 27-34.	0.4	15
6	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5 . 5	207
7	Federation Pharmacological Safety in Pregnancy: Modern Knowledge, Practice and Pharmacoepidemiological Approaches to the Studying and Recognizing of Drugs with Teratogenic Risk. PediatriÄeskaâ Farmakologiâ, 2019, 16, 19-29.	0.1	O
8	One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine, 2018, 36, 381-387.	1.7	21
9	COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015. Rational Pharmacotherapy in Cardiology, 2018, 14, 21-26.	0.3	O
10	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	13.9	2,211
11	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Annals of the Rheumatic Diseases, 2017, 76, 1009-1019.	0.5	180
12	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510
13	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	1.6	40
14	Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs. PediatriÄeskaâ Farmakologiâ, 2017, 14, 127-141.	0.1	3
15	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	13.9	379
16	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	13.9	2,261
17	PHARMACOTHERAPY AND OUTCOMES OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION – GENDER DIFFERENCES IN REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2013, 9, 650-654.	0.3	O
18	FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, iii19-iii32.	1.3	112